依託孕烯(英語:Etonogestrel)是一種人工合成的甾體有機化合物,化學式C22H28O2,可作為依託孕烯植入器的藥物用於女性避孕[9]

依託孕烯
臨床資料
商品名英語Drug nomenclatureCirclet, Implanon, Nexplanon, others
其他名稱ORG-3236; SCH-900702 (with EE); 3-Ketodesogestrel; 3-Oxodesogestrel; 11-Methylenelevonorgestrel;[1] 11-Methylene-17α-ethynyl-18-methyl-19-nortestosterone; 11-Methylene-17α-ethynyl-18-methylestr-4-en-17β-ol-3-one
AHFS/Drugs.com專業藥物信息
MedlinePlusa604032
懷孕分級
給藥途徑皮下植入器英語Subcutaneous implant陰道環
藥物類別英語Drug class黃體酯酮 (藥物)英語Progestogen (medication); 黃體素
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度植入:100%[4]
陰道環:100%[5]
血漿蛋白結合率≥98%(66%與白蛋白英語human serum albumin,32%與性激素結合球蛋白)結合[4]
藥物代謝肝臟CYP3A4[4][5]
生物半衰期21–38小時[6][7][8][4][5]
排泄途徑尿(主)、糞便(少)[4][5]
識別資訊
  • (8S,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
CAS號54048-10-1  checkY
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.053.561 編輯維基數據鏈接
化學資訊
化學式C22H28O2
摩爾質量324.46 g·mol−1
3D模型(JSmol英語JSmol
  • CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
  • InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1 checkY
  • Key:GCKFUYQCUCGESZ-BPIQYHPVSA-N checkY

參考文獻

編輯
  1. ^ Ryan KJ. Kistner's Gynecology and Women's Health. Mosby. 1999: 300. ISBN 978-0-323-00201-1. 
  2. ^ NEXPLANON : Etonogestrel extended release subdermal implant (PDF). Pdf.hres.ca. [2022-06-08]. (原始內容存檔 (PDF)於2022-06-10). 
  3. ^ List of nationally authorised medicinal products : Active substance: etonogestrel : Procedure no.: PSUSA/00001331/202109 (PDF). Ema.europa.eu. [2022-06-08]. (原始內容存檔 (PDF)於2022-06-10). 
  4. ^ 4.0 4.1 4.2 4.3 4.4 Nexplanon- etonogestrel implant. DailyMed. 18 November 2019 [25 September 2020]. (原始內容存檔於10 June 2022). 
  5. ^ 5.0 5.1 5.2 5.3 NuvaRing- etonogestrel and ethinyl estradiol insert, extended release. DailyMed. 24 January 2020 [25 September 2020]. (原始內容存檔於8 August 2020). 
  6. ^ Runnebaum BC, Rabe T, Kiesel L. Female Contraception: Update and Trends. Springer Science & Business Media. 6 December 2012: 156–163. ISBN 978-3-642-73790-9. 
  7. ^ Holtsclaw JA. Progress Towards the Total Synthesis of Desogestrel and the Development of a New Chiral Dihydroimidazol-2-ylidene Ligand. University of Michigan. 2007: 25. In 1981, desogestrel was marketed as a new low dose oral contraceptive under the trade names Marvelon and Desogen.32 
  8. ^ Mosby's GenRx: A Comprehensive Reference for Generic and Brand Prescription Drugs. Mosby. 2001: 687. ISBN 978-0-323-00629-3. The elimination half-life for 3-keto-desogestrel is approximately 38 ± 20 hours at steady state. 
  9. ^ Borsch, Julia. [www.deutsche-apotheker-zeitung.de/news/artikel/2017/08/14/verhuetungsringe-jetzt-auch-ungekuehlt Verhütungsringe jetzt auch ungekühlt] 請檢查|url=值 (幫助). DAZ.online. 2017-08-14. 

外部連結

編輯